Clinical Trial

Pathological Basis of MRI Signal Changes in Multiple Sclerosis

Recruiting
View on ClinicalTrials.gov →
Summary
Background: Multiple sclerosis (MS) is a disease that damages the central nervous system (brain and spinal cord). This leads to increased physical disability over time. The disease is lifelong once it begins. Researchers want to learn more about MS s stages and follow them until a person s death. Objective: To understand how the physical and clinical signs of MS relate to its changes over time. Eligibility: Adults age 18 or older with MS or a disease of the brain and spinal cord that may act like MS. Design: Participants will have a medical history and a complete neurological exam. They may have timed tests of neurological function, such as a 25-foot walk and a 9-hole peg test. Participants will have multi-day visits about once a year. Participants will have blood drawn. Participants may have a brain magnetic resonance imaging (MRI) scan. They may also have an MRI of the spinal cord. They may get a contrast agent (dye) injected into a tube in an arm vein. During the MRI, participants will lie on a table that slides in and out of a metal cylinder. Participants will have the thickness of their retina measured using optical coherence tomography. A camera on top of a table uses lasers. Participants will look through a lens and follow instructions. Eye drops may be used to dilate the pupils. Participants will chew on a piece of sterile cotton for 1 minute to collect saliva. Participants agree to have an autopsy at the time of their death and to donate some of their organs to research, such as the brain and spinal cord.
Protocol Amendment History 140 amendments
This ClinicalTrials.gov record has been amended 140 times since 2016-01-20; most recent amendment 2026-06-04.
Trial Details
NCT Number NCT02659956
Lead Sponsor National Institute of Neurological Disorders and Stroke (NINDS)
Conditions Multiple Sclerosis
Enrollment 250 participants
Start Date 2016-04-07
Primary Completion 2080-02-26 (estimated)
Study Completion 2080-02-26 (estimated)
Updated on ClinicalTrials.gov 2026-06-05